Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy
This population-based study found increased advanced therapies use partially because of the higher IBD prevalence observed during the study period, but with decreasing costs, mainly attributable to the significant use of anti-tumor necrosis factor αlpha biosimilars.
Authors
- N. Antonino
- Eugenio Di Brino (ORCID: https://orcid.org/0000-0001-7964-3348)
- Annamaria Pia Terlizzi (ORCID: https://orcid.org/0000-0002-9160-5376)
- Marcello Covino (ORCID: https://orcid.org/0000-0001-9916-9372)
- Francesca Vittoria Rizzi
- Carlo Casamassima
- W Elisei
- A Tursi
- Carlotta De Chiara
- Federica Di Pierro
- Alfredo Papa
Institutions
- Catholic Medical Center (US)
- Altera (United States) (US)
- Agostino Gemelli University Polyclinic (IT)
- Ospedale degli Infermi (IT)
- Public Health Agency (GB)
- Azienda Sanitaria Locale Alessandria (IT)
- Nini Hospital (LB)
- Carlo Forlanini Hospital (IT)
- San Diego Fertility Center (US)
- Catholic University of America (US)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1097/meg.0000000000003159
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00